A Columbia woman is putting a spotlight on a rare, degenerative disease, which targets the nervous system and often impairs ...

Friedreich ataxia (FA) is a rare, hereditary neurodegenerative disease that causes difficulties with coordination and balance and reduces lifespan. The disease affects approximately 1 in 50,000 ...

The primary endpoint was the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA). Findings showed troriluzole statistically significantly ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in ...

mFARS is designed to assess Friedreich Ataxia progression in clinical trials, focusing on motor function and disease severity. Its complexity and time requirements may limit routine use in ...